Androgen receptor signalling impairs docetaxel efficacy in castration-resistant prostate cancer

Androgen receptor (AR) signalling drives neoplastic growth and therapy resistance in prostate cancer. Recent clinical data show that docetaxel combined with androgen deprivation therapy improves outcome in hormone-sensitive disease. We studied whether testosterone and AR signalling interferes with d...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Br J Cancer
Main Authors: Mout, Lisanne, Moll, Jan M., Chen, Mingqing, de Morrée, Eleonora S., de Ridder, Corrina M. A., Gibson, Alice, Stuurman, Debra, Aghai, Ashraf, Erkens-Schulze, Sigrun, Mathijssen, Ron H. J., Sparreboom, Alex, de Wit, Ronald, Lolkema, Martijn P., van Weerden, Wytske M.
Formato: Artigo
Idioma:Inglês
Publicado em: Nature Publishing Group UK 2020
Assuntos:
Brief Communication
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7722857/
https://ncbi.nlm.nih.gov/pubmed/32989230
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/s41416-020-01105-y
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados